Guardant Multi-Cancer Detection

A single blood draw that screens for early signals across 10 cancers: bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate. Together these account for approximately two-thirds of all cancer-related deaths and include some of the most aggressive cancers.

Many of these cancers have no routine screening pathway today. Where a signal is found, the test also predicts where in the body it may have originated, to help guide the next step with your doctor.

Guardant Health is a global leader in blood-based cancer testing, with over a decade of experience. The Multi-Cancer Detection test is backed by over 1 million oncology blood samples tested and more than 600 peer-reviewed publications.

Intended for adults aged 45 and older with no known diagnosis of cancer. Your clinical eligibility will be determined by the medical provider with whom you have scheduled your appointment.

This test is intended to complement, not replace, guideline-recommended cancer screening. A negative result does not eliminate the possibility that cancer is present or may develop in the future.